HK Stock Market Move | HENLIUS (02696) rises over 5%, self-developed KAT6A/B small molecule inhibitor HLX97 obtains IND approval from the National Medical Products Administration.

HENLIUS (02696) rose by more than 5%, as of the time of writing, it rose by 5.02% to HKD 68, with a turnover of HKD 194.815 million. On the news front, on March 5, HENLIUS announced that its independently developed HLX97 (KAT6A/B small molecule inhibitor) had received approval from the National Medical Products Administration (NMPA) for Phase I clinical trial application in patients with advanced/metastatic solid tumors. HLX97 is a small molecule inhibitor of lysine acetyltransferase 6A/B (KAT6A/B) developed by the company itself, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies have shown that HLX97 can inhibit the activity of KAT6A/B, demonstrating good anti-tumor efficacy and safety characteristics. As of the date of this announcement, there have been no approved KAT6A/B small molecule inhibitors on the market worldwide.